[Psoriasis therapy with fumaric acid and fumaric acid esters].
Fumaric acid may not be regarded as an antipsoriatic drug. Beneficial effects on psoriatic lesions may be explained by secondary changes such as the acidification of gastric juice in cases of anacidity or hypacidity . Monoethylfumarate exerts true antipsoriatic activities but is by far too toxic for clinical use. Experimental investigations have confirmed an inhibitory action of the above-mentioned fumarate on nucleic acid synthesis and protein synthesis of PHA-stimulated human lymphocytes.
D004247:DNA / Q000378:metabolism; D005650:Fumarates / Q000009:adverse effects / Q000627:therapeutic use*; D005745:Gastric Acidity Determination; D006801:Humans; D011506:Proteins / Q000378:metabolism; D011565:Psoriasis / Q000188:drug therapy*
D005650:Fumarates; D011506:Proteins; C035088:diethyl fumarate; C032005:fumaric acid; D004247:DNA
Psoriasis-Behandlung mit Fumarsäure und Fumarsäureestern.